Vortioxetine

• Major Depressive Disorder
• Depression with Cognitive Symptoms
• Mood Disorders

Vortioxetine (brand name Trintellix) is a multimodal antidepressant approved for major depressive disorder in adults. It combines serotonin reuptake inhibition with direct activity at multiple serotonin receptor subtypes, producing antidepressant and possible procognitive effects. For patients who have struggled with sexual side effects, sedation, or cognitive blunting on traditional SSRIs, or who experience prominent attention and processing-speed difficulties as part of their depression, vortioxetine is an evidence-based alternative worth considering. It is taken once daily, has a relatively favorable tolerability profile after the first week, and does not require titration to reach the starting therapeutic dose. Generic vortioxetine is now available in many regions, improving accessibility for long-term treatment.

Mechanism of Action

Vortioxetine acts simultaneously at six distinct serotonin targets. It inhibits the serotonin transporter (SERT) - the same target as SSRIs - which raises synaptic serotonin and accounts for much of its antidepressant effect. It is also a 5-HT3 receptor antagonist, which contributes to reduced nausea (compared with what 5-HT3 stimulation alone would produce) and may enhance hippocampal acetylcholine release relevant to cognition. It antagonizes 5-HT7 receptors, which is associated with circadian rhythm modulation and pro-cognitive effects. It antagonizes 5-HT1D receptors, partial-agonizes 5-HT1B receptors, and full-agonizes 5-HT1A receptors, all of which together modulate serotonin release across cortical and limbic circuits.

The practical clinical implication of this multimodal profile is twofold: first, downstream changes in dopamine, norepinephrine, acetylcholine, and glutamate signaling in cortical regions appear to support measurable improvements in executive function, attention, and processing speed in depressed patients - effects that are partially independent of mood improvement. Second, the receptor-level activity may explain a different side-effect signature than pure SSRIs, with somewhat lower rates of sexual dysfunction and sedation, although nausea is more common in the first week. Trial data and labeling are summarized at DailyMed, and the National Institute of Mental Health provides patient education on depression treatment options. Vortioxetine is metabolized primarily through CYP2D6 with secondary contribution from CYP3A4, CYP2C9, CYP2C19, and CYP2A6, which means CYP2D6 poor metabolizers and patients on strong CYP2D6 inhibitors require dose reductions, while patients on strong CYP inducers may need higher doses.

Clinical Use

For major depressive disorder, vortioxetine is one of many evidence-based first-line options alongside SSRIs such as sertraline, escitalopram, paroxetine, and fluoxetine, and SNRIs such as duloxetine and venlafaxine. It tends to be considered when an SSRI has failed because of inadequate response, sexual side effects, or cognitive complaints, or when cognitive symptoms - difficulty concentrating, slowed thinking, executive dysfunction - are a prominent part of the depressive presentation. Several randomized trials have demonstrated greater improvement in objective cognitive performance with vortioxetine than with placebo, with effects partially separable from mood improvement.

Compared with bupropion, vortioxetine has more nausea but less insomnia and no contraindication in seizure-prone patients. Compared with mirtazapine, it has less weight gain and sedation. Patient selection favors adults with major depressive disorder, particularly those with cognitive complaints, prior sexual dysfunction on SSRIs, or partial response to a previous serotonergic antidepressant. It should not be used within 14 days of an MAOI or 21 days after stopping vortioxetine before starting an MAOI. Patients with bipolar disorder, especially those with rapid cycling, require careful evaluation because all antidepressants can precipitate mania. Patients at high risk of bleeding, on chronic NSAIDs or antiplatelet therapy, or with significant alcohol use need risk-benefit discussion. For lifestyle support that complements pharmacotherapy, see our articles on recognizing burnout and exhaustion and how stress affects your body. Patients with severe baseline insomnia may prefer a more sedating agent at night; those with prominent fatigue may prefer a more activating agent. Pregnancy plans, breastfeeding intentions, and the patient's prior antidepressant history all inform whether vortioxetine is the right starting choice.

How to Take It

The usual starting dose is 10 mg once daily, taken with or without food at any consistent time. Many patients prefer morning dosing because of mild activation, while others find evening dosing helpful. After one to two weeks, the dose may be increased to 20 mg daily for patients tolerating 10 mg well. For patients with intolerable nausea or other adverse effects, the dose may be reduced to 5 mg daily. The 20 mg dose is associated with greater efficacy in many trials but slightly higher rates of nausea and other side effects.

If a dose is missed and remembered the same day, take it; if it is the following day, skip and resume the schedule - never double up. The first week typically brings nausea in roughly a quarter of patients; this is most pronounced in the first few days and almost always resolves over one to two weeks. Taking the dose with food, splitting morning toast or yogurt around the dose, and ensuring adequate hydration help. Mood improvement usually emerges over two to four weeks, with cognitive benefits sometimes appearing later. When discontinuing 15 to 20 mg doses, taper to 10 mg for about a week before stopping to reduce withdrawal-like symptoms. Store tablets at room temperature. Patients should be reminded that antidepressants in general work best when taken consistently for at least four to six weeks before judging effectiveness, and that early activation, mild GI symptoms, or transient sleep changes do not necessarily mean the drug will not work. Alcohol should be limited because it can blunt benefit and worsen sleep.

Monitoring and Follow-Up

A baseline depression severity assessment using the PHQ-9 is recorded before starting and reassessed at 2, 4, 8, and 12 weeks. Suicidality screening is mandatory at each visit, particularly in patients under 25 because of the boxed warning regarding increased suicidal thinking in young patients. Sleep, appetite, energy, concentration, and side effects including nausea, sexual function, and bleeding tendency are reviewed at each visit. A baseline complete blood count and basic metabolic panel are reasonable in older patients, with sodium specifically tracked because of SIADH risk in elderly patients on serotonergic agents.

For patients with cognitive complaints, formal testing - the Digit Symbol Substitution Test, for instance - can be useful at baseline and at 8 to 12 weeks to document objective improvement. Response is typically defined as 50 percent reduction in PHQ-9 score; remission as a score below 5. Inadequate response by 6 to 8 weeks at the maximum tolerated dose suggests dose increase, augmentation, or switch. CYP2D6 genotyping is not routinely required but is considered when a patient has had unusual adverse effects or response patterns - poor metabolizers should not exceed 10 mg daily, and patients on strong CYP2D6 inhibitors such as bupropion, fluoxetine, or paroxetine require dose halving. Annual reassessment of ongoing need is appropriate; most patients with single-episode major depression continue treatment for at least 6 to 12 months after remission, while those with recurrent depression often continue indefinitely. Patients should be specifically asked about new bleeding tendency at each visit because serotonin reuptake inhibitors interfere with platelet function and can amplify bleeding risk in those on NSAIDs, antiplatelet drugs, or anticoagulants.

Special Populations

No dose adjustment is needed for renal impairment or for mild to moderate hepatic impairment; severe hepatic impairment is not formally studied and warrants caution. Elderly patients require no automatic adjustment but are at higher risk for hyponatremia and falls; slower titration and lower target doses are reasonable. Pediatric safety and efficacy are not established. Pregnancy data are limited; third-trimester exposure can produce neonatal serotonergic withdrawal symptoms that resolve over days, and the decision to continue during pregnancy weighs maternal risk of relapse against fetal exposure. Lactation data show drug presence in breast milk; risk-benefit discussion is required.

CYP2D6 poor metabolizers should not exceed 10 mg daily. Strong CYP inducers such as rifampin, carbamazepine, or phenytoin can substantially lower vortioxetine levels - the dose may need to be increased up to threefold. Concurrent use with other serotonergic agents - SSRIs, SNRIs, tramadol, triptans, linezolid, or St. John's wort - increases serotonin syndrome risk. Patients with a personal or family history of bipolar disorder require careful evaluation before any antidepressant; vortioxetine alone is not appropriate as monotherapy in bipolar depression. Patients with active substance use disorders, particularly alcohol, often experience suboptimal response and benefit from concurrent addiction treatment. Patients with seizure disorders may take vortioxetine with reasonable safety, although case reports of activation exist. Patients with a recent acute coronary event were not extensively studied; cautious initiation with attentive monitoring is reasonable.

When to Contact Your Doctor

Call the office immediately for new or worsening suicidal thoughts or behavior changes, particularly in the first weeks of treatment or after dose changes. Symptoms of serotonin syndrome - agitation, confusion, rapid heart rate, fever, muscle rigidity, tremor, diarrhea - require urgent evaluation. Unusual bruising, prolonged bleeding from cuts, blood in stool or urine, or nosebleeds suggest bleeding tendency. Severe nausea preventing oral intake, signs of hyponatremia such as headache, confusion, weakness, or seizures, manic symptoms including decreased need for sleep, racing thoughts, or impulsivity, and any new eye pain with vision changes suggesting acute angle-closure glaucoma all warrant prompt contact. Allergic symptoms including rash, swelling, or difficulty breathing require emergency care.

If you would like to discuss whether vortioxetine is the right antidepressant choice for your symptoms or to review your current regimen, contact us or schedule a visit with our internal medicine team.